Montelukast Unimark (Montelukast)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes from binding and triggering bronchial smooth‑muscle contraction, mucus secretion, and airway inflammation. By inhibiting this pathway, the drug reduces airway narrowing and inflammatory responses, leading to improved breathing and fewer allergy‑related symptoms.

The appropriate dose of Montelukast Unimark is determined by the prescribing clinician based on the patient’s age, weight, indication, and overall clinical status. Dosage recommendations are outlined in the product’s prescribing information, but the final regimen is individualized and should be confirmed by a qualified healthcare professional.

Safety data for Montelukast in pregnancy are limited, and the product is generally classified as a drug with unknown pregnancy risk. It should be used only if the potential benefit justifies any possible risk to the fetus. Excretion in breast milk is also not well defined, so a risk‑benefit assessment is required for nursing mothers.

To place an order, submit an enquiry on the Montelukast Unimark product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids and long‑acting beta‑agonists. While it is less potent than high‑dose inhaled steroids for severe asthma, it provides convenient once‑daily dosing and is especially useful for patients with aspirin‑exacerbated respiratory disease or those who prefer an oral regimen.

Montelukast Unimark should be stored at ambient temperature below 25 °C, protected from moisture and light. Keep the tablets in the original blister pack until use, and avoid storing them in bathrooms or other humid environments. Do not freeze the product.

Montelukast Unimark is supplied as oral tablets that are swallowed whole with water. The medication is taken once daily, preferably in the evening, unless the prescriber advises a different schedule. No food restrictions are required, but the tablet should not be chewed or crushed.

Serious adverse reactions, although rare, include angioedema, Stevens‑Johnson syndrome, and eosinophilic granulomatosis with polyangiitis. Neuropsychiatric events such as mood changes, depression, or suicidal thoughts have also been reported. Patients should be instructed to seek immediate medical attention if they experience swelling of the face or throat, skin rash, or significant changes in mood.

Montelukast Unimark is contraindicated in patients with known hypersensitivity to montelukast or any of the tablet excipients. It is also not recommended for children younger than 12 months of age. Caution is advised in patients with severe hepatic impairment, and clinicians should evaluate the risk‑benefit profile before prescribing.